Summit Therapeutics PLC (NASDAQ:SMMT) has earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $25.00.

Several research firms have recently commented on SMMT. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Summit Therapeutics PLC in a research note on Wednesday, March 22nd. ValuEngine raised Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th. Canaccord Genuity reissued a “buy” rating and issued a $28.00 target price on shares of Summit Therapeutics PLC in a research note on Friday, June 16th. Finally, Zacks Investment Research cut Summit Therapeutics PLC from a “buy” rating to a “hold” rating in a research note on Saturday, April 1st.

An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Acadian Asset Management LLC acquired a new position in Summit Therapeutics PLC (NASDAQ:SMMT) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,850 shares of the company’s stock, valued at approximately $171,000. Acadian Asset Management LLC owned about 0.10% of Summit Therapeutics PLC as of its most recent SEC filing. Institutional investors and hedge funds own 21.86% of the company’s stock.

Shares of Summit Therapeutics PLC (NASDAQ:SMMT) traded up 4.8666% during mid-day trading on Friday, hitting $12.5001. The stock had a trading volume of 15,017 shares. The stock’s market cap is $154.76 million. The firm’s 50-day moving average price is $11.23 and its 200 day moving average price is $11.14. Summit Therapeutics PLC has a 12-month low of $5.31 and a 12-month high of $19.75.

TRADEMARK VIOLATION WARNING: “Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of “Buy” by Brokerages” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/07/14/summit-therapeutics-plc-nasdaqsmmt-given-consensus-recommendation-of-buy-by-brokerages.html.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Analyst Recommendations for Summit Therapeutics PLC (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.